These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23279235)

  • 1. Allergy to IXIARO and BIKEN Japanese encephalitis vaccines.
    McCallum AD; Jones ME
    J Travel Med; 2013; 20(1):60-2. PubMed ID: 23279235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up.
    Dubischar-Kastner K; Kaltenboeck A; Klingler A; Jilma B; Schuller E
    Vaccine; 2010 Sep; 28(39):6463-9. PubMed ID: 20673824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis.
    Erra EO; Kantele A
    Expert Rev Vaccines; 2015; 14(9):1167-79. PubMed ID: 26162529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
    Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
    Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new inactivated Japanese encephalitis vaccine for adult travelers.
    Toovey S
    Travel Med Infect Dis; 2009 Sep; 7(5):301-4. PubMed ID: 19747666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
    Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
    Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO
    Jelinek T; Cromer MA; Cramer JP; Mills DJ; Lessans K; Gherardin AW; Barnett ED; Hagmann SHF; Askling HH; Kiermayr S; Kadlecek V; Eder-Lingelbach S; Taucher C; Dubischar KL
    Travel Med Infect Dis; 2018; 22():18-24. PubMed ID: 29549036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new Japanese encephalitis vaccine (Ixiaro).
    Med Lett Drugs Ther; 2009 Aug; 51(1319):66-7. PubMed ID: 19696707
    [No Abstract]   [Full Text] [Related]  

  • 9. Product review on the JE vaccine IXIARO.
    Firbas C; Jilma B
    Hum Vaccin Immunother; 2015; 11(2):411-20. PubMed ID: 25621812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines.
    Erra EO; Askling HH; Rombo L; Riutta J; Vene S; Yoksan S; Lindquist L; Pakkanen SH; Huhtamo E; Vapalahti O; Kantele A
    Clin Infect Dis; 2012 Sep; 55(6):825-34. PubMed ID: 22696017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on Japanese encephalitis vaccine for children: United States, May 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 May; 60(20):664-5. PubMed ID: 21617633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IXIARO updated: overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis.
    Jelinek T
    Expert Rev Vaccines; 2013 Aug; 12(8):859-69. PubMed ID: 23984958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated).
    Kikukawa A; Gomi Y; Akechi M; Onishi T; Manabe S; Namazue J; Fuke I; Ishikawa T; Okuno Y; Ueda S
    Vaccine; 2012 Mar; 30(13):2329-35. PubMed ID: 22306856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age.
    Kaltenböck A; Dubischar-Kastner K; Schuller E; Datla M; Klade CS; Kishore TS
    Vaccine; 2010 Jan; 28(3):834-9. PubMed ID: 19857447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO(®).
    Schuller E; Klingler A; Dubischar-Kastner K; Dewasthaly S; Müller Z
    Vaccine; 2011 Nov; 29(47):8669-76. PubMed ID: 21907747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Sabchareon A; Pancharoen C; Bouckenooghe A; Gailhardou S; Boaz M; Feroldi E
    Pediatr Infect Dis J; 2010 Dec; 29(12):1111-7. PubMed ID: 20856164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children: An Open-label, Randomized, Active-controlled, Phase 3 Study.
    Dubischar KL; Kadlecek V; Sablan B; Borja-Tabora CF; Gatchalian S; Eder-Lingelbach S; Mueller Z; Westritschnig K
    Pediatr Infect Dis J; 2017 Sep; 36(9):889-897. PubMed ID: 28441266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Japanese encephalitis vaccine in travelers.
    Jelinek T
    Expert Rev Vaccines; 2008 Jul; 7(5):689-93. PubMed ID: 18564023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of Japanese encephalitis disease and its prevention. Focus on IC51 vaccine (IXIARO
    Amicizia D; Zangrillo F; Lai PL; Iovine M; Panatto D
    J Prev Med Hyg; 2018 Mar; 59(1):E99-E107. PubMed ID: 29938245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.